Regulatory mechanisms of hypoxia-inducible factor 1 activity: Two decades of knowledge by Koyasu, Sho et al.
TitleRegulatory mechanisms of hypoxia-inducible factor 1 activity:Two decades of knowledge
Author(s)Koyasu, Sho; Kobayashi, Minoru; Goto, Yoko; Hiraoka,Masahiro; Harada, Hiroshi




© 2017 The Authors. Cancer Science published by John Wiley
& Sons Australia, Ltd on behalf of Japanese Cancer
Association. This is an open access article under the terms of
the Creative Commons Attribution‐NonCommercial License,
which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not




R E V I EW AR T I C L E
Regulatory mechanisms of hypoxia-inducible factor 1 activity:
Two decades of knowledge
Sho Koyasu1,2 | Minoru Kobayashi1 | Yoko Goto3 | Masahiro Hiraoka3 |
Hiroshi Harada1,4
1Laboratory of Cancer Cell Biology,
Department of GenomeDynamics, Radiation
Biology Center, KyotoUniversity, Kyoto, Japan
2Research Center for Advanced Science and
Technology, The University of Tokyo,
Tokyo, Japan
3Department of Radiation Oncology and
Image-applied Therapy, Kyoto University
Graduate School of Medicine, Kyoto, Japan
4Precursory Research for Embryonic
Science and Technology, Japan Science and
Technology Agency (JST), Saitama, Japan
Correspondence
Hiroshi Harada, Laboratory of Cancer Cell
Biology, Department of Genome Dynamics,




Sho Koyasu and Minoru Kobayashi
contributed equally to this work.
Funding information
H.H. was supported by the program for
Precursory Research for Embryonic Science
and Technology (PRESTO) from the Japan
Science and Technology Agency (JST) (No.
JPMJPR14M8), by the Research Project on
the Development of New Drugs from the
Japan Agency for Medical Research and
Development (AMED) (No.
17ak0101084 h0001), by the Bilateral Joint
Research Projects from JSPS, by Grants-in-
Aid for Scientific Research (B) (Nos.
26293276; 17H04261), for Living in Space
(No. 16H01640), for Conquering Cancer
Hypoxia-inducible factor 1 (HIF-1) is a transcriptional activator of various genes
related to cellular adaptive responses to hypoxia. Dysfunctions in the regulatory sys-
tems of HIF-1 activity have been implicated in the pathogenesis of various diseases
including malignant tumors and, thus, elucidating the molecular mechanisms underly-
ing the activation of HIF-1 is eagerly desired for the development of novel anti-can-
cer strategies. The importance of oxygen-dependent and ubiquitin-mediated
proteolysis of the regulatory subunit of HIF-1 (HIF-1a) was first reported in 1997.
Since then, accumulating evidence has shown that HIF-1a may become stable and
active even under normoxic conditions; for example, when disease-associated
genetic and functional alterations in some genes trigger the aberrant activation of
HIF-1 regardless of oxygen conditions. We herein review the last two decades of
knowledge, since 1997, on the regulatory mechanisms of HIF-1 activity from con-
ventional oxygen- and proteolysis-dependent mechanisms to up-to-the-minute
information on cancer-associated genetic and functional alteration-mediated
mechanisms.
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1 | INTRODUCTION
The existence of a hypoxia-inducible transcriptional factor was first
predicted in 1991 through an investigation on the cis-acting regula-
tory elements of the human erythropoietin gene (Epo), the expres-
sion of which is known to be induced under hypoxic conditions1,2
(Figure 1). Wang and Semenza subsequently succeeded in purifying
the responsible factor in 1995, identified it as a heterodimer com-
posed of approximately 120-kDa and 90-kDa proteins, and desig-
nated them as HIF-1a and HIF-1b, respectively (Figure 1)3. Since
then, HIF-1 has been shown to play important roles in the growth
and malignant progression of tumors by inducing the transcription of
hundreds of genes that function in improving oxygen availability in
tumor tissues (angiogenesis/neovascularization4-7), the escape of
cancer cells from tumor hypoxia (invasion and metastasis of cancer
cells5,8,9), and the adaption of cancer cells to a hypoxic microenviron-
ment (metabolic reprogramming7,10-14). As a result of these diverse
functions of its downstream genes, HIF-1 has been widely recog-
nized as a rational target for cancer therapy5,15,16 and, thus, marked
efforts have been devoted to elucidating the molecular mechanisms
underlying its activation.
Regulatory mechanisms, which have the biggest impact on HIF-
1 activity, are regulated through post-translational modifications to
the HIF-1a protein (Figure 2). The hydroxylation of HIF-1a by oxy-
gen-, iron-, and 2-oxoglutarate (2OG)-dependent dioxygenase
enzymes at two specific proline residues (P402 and P564) and one
specific asparagine residue (N803) leads to proteolysis and a
decrease in the transactivation activity of HIF-1a, respectively,
such that HIF-1 may express its transcriptional activity under
hypoxic conditions.17-20 Consequently, the expression of HIF-1a
itself and its downstream genes are detected in hypoxic regions,
which are located 70-100 lm from functional blood vessels in
malignant solid tumors.21 However, the expression of HIF-1a is
often observed regardless of the distance from functional tumor
blood vessels (and potentially regardless of oxygen availability) in
immunohistochemical analyses of clinical tumor samples.22 These
findings suggest that there are mechanisms other than the above-
described hypoxia-dependent mechanism. In the last decade, HIF-1
activity has consistently been reported to be regulated not only at
the post-translational level in an oxygen-dependent way, but also
at other levels, such as transcription initiation, translation initiation,
heterodimer formation, translocation into the nucleus, and transac-
tivation, regardless of the surrounding oxygen conditions.11 More-
over, prolyl- and asparagine-hydroxylation-mediated decreases in
HIF-1 activity were shown to be abrogated, even in the presence
of oxygen, in some cases.7,23,24 We herein review the last two
decades of knowledge on the regulatory mechanisms of HIF-1
activity including not only well-established oxygen- and hydroxyla-
tion-dependent mechanisms, but also up-to-the-minute information
on cancer-associated genetic and functional alteration-mediated
mechanisms.
2 | CONVENTIONAL DOGMA REGARDING
DIOXYGENASE-DEPENDENT REGULATION
OF HIF-1 ACTIVITY
After HIF-1 was reported to be a heterodimer,3 HIF-1a was recog-
nized as the main regulatory subunit for HIF-1 activity, whereas HIF-
1b was a constitutively expressed subunit. Although the expression
levels of HIF-1a are now known to be regulated at multiple levels,
the initially elucidated and most influential molecular mechanism on
HIF-1 activity is that mediated by the dioxygenase-dependent and
ubiquitin-proteasome pathway-mediated system (Figures 1 and 2).
Two proline residues positioned at amino acids (a.a.) 402 and 564 of
HIF-1a are hydroxylated by dioxygenases, called PHD (including
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PHD1-3), in an oxygen-dependent way (Figures 2 and 3).17,19,20 Pro-
lyl hydroxylation triggers a ubiquitination reaction by pVHL-contain-
ing E3 ubiquitin ligase, leading to the proteolysis of HIF-1a through
the ubiquitin-proteasome system with a half-life of 6-8 min (Fig-
ure 2).25-27 As HIF-1 promotes angiogenesis by inducing the expres-
sion of proangiogenic factors, such as VEGF, this mechanism appears
to be reasonable from the viewpoint of a characteristic feature of
VHL disease whereby a deficiency in functional VHL as a result of a
mutation in chromosome 3p25.3 causes vascular-rich
hemangioblastomas, renal cell carcinomas (mainly clear cell carcino-
mas), and pheochromocytomas.28,29
In addition to the proteolytic mechanism triggered by PHD,
another dioxygenase, FIH-1, was found to play a key role in the
inactivation of HIF-1 under normoxic conditions (Figures 2 and 3).
FIH-1 hydroxylates the asparagine residue positioned at a.a. 803 of
HIF-1a in an oxygen-dependent way, and suppresses recruitment of
the transcriptional co-activator complex, p300/CBP acetyltrans-
ferases, to the HIF-1a protein.30,31 Thus, asparagine hydroxylation
F IGURE 1 History of hypoxia-inducible factor 1 (HIF-1) biology in the first era. Gregg L. Semenza, William G. Kaelin, Jr, and Peter J.
Ratcliffe have contributed to elucidating the molecular mechanism responsible for HIF-1-mediated adaptive responses to hypoxia in the first
era of HIF-1 biology. The importance of the oxygen-dependent and ubiquitin-mediated proteolysis of hypoxia-inducible factor 1a (HIF-1a) was
first reported by Salceda and Caro 20 years ago in 1997.79 VHL, von Hippel-Lindau. Images courtesy of the Albert and Mary Lasker
Foundation
F IGURE 2 Conventional oxygen- and
dioxygenase-dependent regulatory
mechanisms for hypoxia-inducible factor 1
(HIF-1) activity. FIH-1, factor-inhibiting
HIF-1; HIF-1a, hypoxia-inducible factor 1a;
HIF-1b, hypoxia-inducible factor 1b; PHD,
prolyl-4-hydroxylase; VHL, von Hippel-
Lindau
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results in the inactivation of the transactivation activity of HIF-1a
under normoxic conditions.
Under hypoxic conditions, as a result of decreases in the hydrox-
ylation activity of prolyl and asparagine dioxygenases, HIF-1a
becomes stable and acquires transactivation activity (Fig-
ure 2).17,19,20,30,31 The active form of HIF-1a then translocates into
the nucleus and interacts with its partner subunit, HIF-1b. The resul-
tant heterodimer, HIF-1, induces the transcription initiation of hun-
dreds of genes by binding to their enhancer element, HRE, which is
located in or around the promoter region of each HIF-1-regulated
gene.32,33
Although PHD and FIH-1 both function as sensors of oxygen
concentrations and down-regulate the expression and transactivation
activity of HIF-1a with their hydroxylation activities, their Km values
differ from each other.34,35 As the Km value of FIH-1 is markedly
lower than that of PHD, the HIF-1a protein initially accumulates
under mild hypoxic conditions (e.g. treatment with 1% oxygen for
5 hours35,36) because of decreases in the enzymatic activities of
PHD. It then acquires transactivation activity by interacting with
p300/CBP under severely hypoxic conditions as a result of the inac-
tivation of FIH-1 (e.g. treatment with 0.2% oxygen for 5 hours35,36),
eventually showing maximum transcriptional activity.
3 | GENETIC, MECHANISTIC, AND
FUNCTIONAL ALTERATION-MEDIATED
MECHANISMS
Dioxygenase activities of PHD and FIH-1 are dependent not only on
oxygen, but also on 2OG (also known as a-ketoglutarate) and ferrous
ions (Fe2+); therefore, HIF-1 becomes active in their absence, even
under normoxic conditions. In addition, genetic, mechanistic, and/or
functional alterations in genes that potentially influence intracellular
levels of oxygen, 2OG, or Fe2+ or that directly influence the rates of
the neo-synthesis or degradation of HIF-1a have been reported to
up-regulate HIF-1 activity and subsequently promote the malignant
progression of tumors. We herein review the following accumulated
information (Figure 3; Tables 1-3).
(A)
(B)
F IGURE 3 Schematic diagram showing the primary structure and hydroxylated (OH), SUMOylated (Sumo), phosphorylated (P), acetylated
(Ac), nitrosylated (NO), and methylated (Me) amino acid residues of the hypoxia-inducible factor 1a (HIF-1a) protein. Gene symbols
represented in red and blue indicate positive and negative regulators of hypoxia-inducible factor 1 (HIF-1), respectively. Factors are categorized
into 4 groups by dashed squares according to the levels to which HIF-1 activity is regulated; at the level of protein stability (A), interactions
with hypoxia-inducible factor 1b (HIF-1b) (B), nuclear translocation (B), and transactivation activity (B). CK1d, casein kinase 1d; C-TAD, C-
terminal transactivation domain; FIH-1, factor-inhibiting HIF-1; GSK-3, glycogen synthase kinase 3; HLH, helix-loop-helix; ID, inhibitory domain;
IDH, isocitrate dehydrogenase; LSD1, lysine-specific demethylase-1; N-TAD, N-terminal transactivation domain; NQO1, NAD(P)H:quinone
oxidoreductase 1; ODD, oxygen-dependent degradation; PAS, Per-Arnt-Sim; PCAF, p300/CBP-associated factor; PHD, prolyl-4-hydroxylase;
PLK3, polo-like kinase 3; RSUME, RWD-containing SUMOylation enhancer; SDH, succinate dehydrogenase; SENP, sentrin/SUMO-specific
protease; SIRT, sirtuin
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3.1 | Mechanisms regulating HIF-1a mRNA levels
Transcription initiation is generally regarded as one of the most
influential steps affecting the expression levels of genes. It is typi-
cally stimulated by one or multiple transcription factors that bind
to a cognate enhancer sequence in its target promoter region.
Transcription of the HIF-1a gene is not an exception, although
basal levels of HIF-1a may be assured regardless of oxygen avail-
ability. Previous studies reported that each transcription factor,
such as the ISGF3 complex, which is composed of STAT1/STAT2/
IRF9,37 STAT3,38 or NF-jB,39 binds to the promoter region of the
HIF-1a gene in order to activate its transcription initiation
(Table 1). Moreover, the PI3K/Akt/PKC/HDAC pathway was also
shown to be involved in the up-regulation of HIF-1a transcription
when cells had the G13997A mutation in the mitochondrial ND6
gene40 (Table 1). We also identified LY6E as an upstream activator
of HIF-1a transcription6 (Table 1). Another mechanism may exist
whereby tumor-associated CpG demethylation facilitates the posi-
tive autoregulation of HIF-1a expression at the transcription level.
For example, Koslowski et al41 found that the HIF-1a promoter
itself possesses an HRE, which is normally repressed by the
methylation of a CpG dinucleotide located in the core element in
normal cells, but, in contrast, is frequently and aberrantly activated
by demethylation in colon cancer cell lines and primary colon can-
cer specimens, enabling the binding of HIF-1a to its own pro-
moter, which results in the autotransactivation of HIF-1a
expression (Table 1). However, negative regulators of the tran-
scription initiation of the HIF-1a gene have been reported. An
example is NRF-1; after binding to the HIF-1a promoter region,
NRF-1 represses its transcription initiation42 (Table 1).
In addition to the regulation of transcription initiation efficiency,
that for mRNA stability is a key determinant of mRNA expression
levels. Regarding HIF-1a mRNA stability, among processing body (P-
body) components, USP52/PAN2 was found to stabilize HIF-1a
mRNA by interacting with (or at least by co-localizing with) the 30-
untranslated region (UTR) of HIF-1a mRNA, leading to an increase in
HIF-1a protein levels43 (Table 1).
3.2 | Mechanisms regulating the translation
initiation of the HIF-1a gene
Translation initiation is another important regulatory step for gene
expression, as shown in the regulation of HIF-1a expression levels.
Translation is initiated through a cap-dependent or IRES-dependent
mechanism.44 Regarding HIF-1a, the PI3K/Akt pathway was shown
to affect and up-regulate the translational initiation of the HIF-1a
protein45-47 (Table 1). YB-1 was also found to directly bind to a
unique secondary structure of the 50UTR of HIF-1a mRNA and
enhance its translation initiation48 (Table 1). Moreover, when acti-
vated through replicative stress under hypoxic conditions, ATR was
shown to stimulate the translation initiation of the HIF-1a protein
through a cis-acting element contained in the HIF-1a open reading
frame49 (Table 1).
3.3 | Mechanisms regulating HIF-1a protein
stability
The molecular mechanisms regulating the stability of HIF-1a have
the greatest impact on HIF-1 activity. In around 2000, the factors
responsible, such as VHL and PHD, were cloned one after another,
as described earlier17,19,20,25,26 (Figure 1). Several gene products with
the potential to influence the effects of these two factors on HIF-1a
were subsequently identified as novel indirect modulators of HIF-1
activity.
3.3.1 | Mechanisms affecting HIF-1a stability by
modulating its prolyl-hydroxylation status
As PHD need oxygen and 2OG as substrates and Fe2+ and ascorbate
as co-factors for their dioxygenase effects on P402 and P564 of
HIF-1a (Figure 2), gene products that influence the intracellular
levels of these molecules have been shown to modulate HIF-1 activ-
ity. 2OG is an intermediary metabolite of the TCA cycle; therefore,
functional disorders in three key enzymes in the TCA cycle, SDH,
FH, and IDH, were found to affect the activities of PHD and subse-
quently HIF-1 as follows23,24 (Table 2). Loss-of-function mutations in
SDH and FH, which have been detected in “hereditary paragan-
glioma” and “hereditary leiomyomatosis and renal cell cancer”, were
shown to cause abnormal accumulation of succinate and fumarate,
respectively.23,24 The accumulated metabolites inhibited PHD
through product inhibition, whereby the product of an enzymatic
reaction directly binds to the enzyme and inhibits its activity for neg-
ative feedback regulation, and eventually leads to the stabilization of
HIF-1a23,24 (Table 2). IDH has three isoforms, IDH1-3, and their
functional disorders or aberrant overexpression influences the func-
tion of PHD because of the structural similarity between 2OG and
2HG. Mutations in IDH1/2 have been detected in gliomas or other
hematological malignancies.50 Although the mutant forms of IDH1/2
have been shown to produce 2HG, it currently remains unclear
whether 2HG activates or inhibits the activity of PHD or is depen-
dent on the enantiomer, D or L (R or S). For example, Koivunen
et al51 showed that L-2HG inhibits PHD activity, leading to an
increase in HIF-1a levels, whereas D-2HG promotes PHD (Table 1).
Meanwhile, Burr et al52 reported similar, but controversial, findings
showing that L-2HG inhibits PHD, whereas D-2HG has no effect
(Table 2). Regarding IDH3, we found that the aberrant activation of
wild-type IDH3 inactivated PHD activity by decreasing intracellular
levels of 2-OG, resulting in the stabilization of HIF-1a7 (Table 2).
Another mechanism has been reported whereby hydroxylation of
the two proline residues is actively regulated in order to control the
stability of HIF-1a without directly inhibiting the enzymatic activities
of PHD. NQO1 was recently identified as a responsible gene53 (Fig-
ure 3A; Table 2). Although NQO1 was originally cloned as a cytoso-
lic reductase, a recent study showed that it binds to the ODD
domain of HIF-1a, physically prevents HIF-1a from interacting with
PHD, and eventually inhibits the proteasome-mediated degradation
of HIF-1a.53 In an experimental mouse model, knockdown of NQO1
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in human colorectal and breast cancer cell lines resulted in suppres-
sion of HIF-1 signaling and tumor growth. Clinically, overexpression
of NQO1 is associated with poor prognosis of patients with various
cancers.54,55
Sirtuin 2, which was originally cloned as an isoform of a family of
NAD(+)-dependent protein deacetylases that regulate cellular metabo-
lism in response to stress, was recently shown to destabilize HIF-1a
using its deacetylase activity56 (Figure 3A; Table 2). SIRT2 has been
shown to directly interact with HIF-1a in order to deacetylate HIF-1a
at K709 and enhance the interaction of HIF-1a with PHD2. SIRT2
overexpression was consistently confirmed to destabilize HIF-1a by
promoting prolyl-hydroxylation, whereas the HIF-1a protein was
maintained at high levels when SIRT2 was deficient or when the acety-
lation-defective mutation, K709R, was introduced into HIF-1a.
3.3.2 | Mechanisms affecting HIF-1a stability
without modulating its prolyl-hydroxylation status
Another type of regulatory mechanism of HIF-1a stability is not
mediated by the conventional PHD-VHL system.
A previous study reported that the molecular chaperone 90 kDa
HSP90 and RACK1 competitively function to regulate the stability of
HIF-1a in a PHD-VHL-independent way57 (Table 2). As HSP90
works to protect HIF-1a from the PHD-VHL-independent degrada-
tion of HIF-1a, RACK1-mediated dissociation of HSP90 from the
Per-Arnt-Sim A (PAS-A) domain of HIF-1a and subsequent recruit-
ment of the Elongin-B/C ubiquitin ligase complex to HIF-1a may
destabilize HIF-1a.
Accumulating evidence has shown that phosphorylation of specific
serine and threonine residues of HIF-1a, S551, T555, and S589, all of
which are located within the ODD domain, plays an important role in
the PHD-VHL-independent destabilization of HIF-1a stability. Glycogen
synthase kinase 3 was identified as the gene responsible for phosphory-
lation based on the finding that the pharmacological inhibition or deple-
tion of GSK-3 induced HIF-1a, whereas overexpression of GSK-3b
reduced HIF-1a, and that mutations in the phosphorylation residues,
S551A/T555V/S589A, abolished the destabilization of HIF-1a58 (Fig-
ure 3A; Table 2). This conclusion was further supported by the finding
that GSK-3-mediated destabilization of HIF-1a was independent of the
hydroxylation sites within HIF-1a (P402/P564/N803) and pVHL.
TABLE 1 Positive and negative regulators of hypoxia-inducible factor 1 (HIF-1) functioning at transcriptional initiation, transcript stability,




activity Regulatory mechanisms for HIF-1 activity Reference
Transcription initiation of the hif-1a gene
ISGF3 (STAT1/STAT2/IRF9) Positive Binding to the promoter region of the hif-1a gene
to activate transcription initiation
37
STAT3 Positive Binding to the promoter region of the hif-1a gene to
activate transcription initiation
38
NF-jB Positive Binding to the promoter region of the hif-1a gene to
activate transcription initiation
39
PI3K/Akt/PKC/HDAC pathway Positive Up-regulating transcription initiation in case of the
G13997A mutation in mitochondrial ND6 gene
40
LY6E Positive Activating the PI3K/Akt pathway through a decrease
in PTEN expression
6
HIF-1 Positive Binding to HRE in the promoter regions of the hif-1a
gene for positive autoregulation
41
NRF-1 Negative Binding to the promoter region of the hif-1a gene to
repress transcription initiation
42
Stability of the hif-1a transcript (mRNA)
P-bodies (USP52/PAN2) Positive Interacting with the 30-UTR of HIF-1a mRNA for its stabilization 43
Translation initiation of the hif-1a gene
PI3K/Akt pathway Positive Up-regulating cap-dependent and IRES-dependent
translation initiation
45-47
YB-1 Positive Binding to the unique secondary structure of the 50UTR
of HIF-1a mRNA to enhance translation initiation
48
ATR Positive Influencing the cis-element in the coding region of HIF-1a
mRNA when activated by replicative stress
49
ATR, ataxia telangiectasia and Rad3-related protein; HDAC, histone deacetylase; HRE, hypoxia-response element; IRES, internal ribosomal entry site;
IRF9, interferon regulatory factor 9; ISGF3, interferon-stimulated gene factor 3; LY6E, lymphocyte antigen 6 complex locus E; ND6, NADH dehydroge-
nase subunit 6; NF-jΒ, nuclear factor kappa B; NRF-1, NF-E2-related factor 1; PAN2, poly(A) nuclease 2; PI3K, phosphoinositide 3-kinase; PKC, protein
kinase C; STAT, signal transducer and activator of transcription; USP52, ubiquitin-specific protease 52; YB-1, Y-box-binding protein 1.
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Other serine residues, S576 and S657, of HIF-1a were also sug-
gested to be phosphorylated and involved in regulation of HIF-1a
stability.59 The responsible modulator is an evolutionarily conserved
serine/threonine kinase, PLK3, which is known to regulate cell cycle
progression through the M phase59,60 (Figure 3A; Table 2). Xu et al
reported that PLK3 physically interacted with HIF-1a under hypoxic
conditions and phosphorylated two serine residues, S576 and S657,
in order to destabilize HIF-1a. PLK3 knock-out MEF were consis-
tently shown to express higher levels of HIF-1a, whereas the phos-
phorylation-resistant mutations, S576A and S657A, stabilized HIF-
1a. In addition, the finding that simultaneous mutations in the prolyl
and Plk3-targeting phosphorylation sites (P402A, P564A, S576A, and
S657A) further increased the levels of HIF-1a strongly suggested
that Plk3 decreases HIF-1a stability in a PHD-independent way.
The SUMOylation of HIF-1a is another post-translational modifi-
cation that affects HIF-1a stability; however, it currently remains
unclear whether SUMOylation increases or decreases the stability of
HIF-1a. Bae et al61 was the first to report in 2004 that SUMOyla-
tion increased HIF-1a stability. They identified K391 and K477 of
HIF-1a as targets of SUMOylation and showed that overexpression
of SUMO-1 increased HIF-1a stability (Figure 3A). In 2007, the
SUMOylation enzyme for HIF-1a, RSUME, was identified and found
to increase the stability of HIF-1a62 (Figure 3A; Table 2). However,
an opposite function of SUMOylation on the stability of HIF-1a was
reported by Cheng et al63 in an analysis of an isoform of SENP,
SENP1 (Figure 3A; Table 2). They showed that SENP1-mediated
deSUMOylation inhibited the interaction between HIF-1a and VHL,
resulting in the stabilization of HIF-1a, suggesting that SUMOylation
leads to HIF-1a proteolysis. Expression levels of HIF-1 downstream
genes were consistently shown to be markedly reduced in MEF and
in mice with the homozygous deletion of SENP1.
Besides the major modifications such as ubiquitination, phosphory-
lation, or SUMOylation described above, methylation also plays a role in
modulating HIF-1a stability that is irrelevant to PHD. A recent study
showed that HIF-1a is methylated by SET7/9 methyltransferase at
K3264 (Figure 3A; Table 2), and LSD1 functions in its demethylation65
(Figure 3A; Table 2). K32 methylation triggers the ubiquitin-mediated
proteolysis of HIF-1a in a PHD-VHL-independent mechanism. Knock-in
mice harboring biallelic methylation-defective K32A mutations in the
HIF-1a gene showed enhanced retinal angiogenesis and tumor vascular-
ization by HIF-1a stabilization, further supporting the importance of
methylation. Mutations near K32 (S28Y and R30Q) of HIF-1a, which
have been detected in human cancers, have also been reported to be
involved in altered HIF-1a stability affecting K32 methylation.64
3.3.3 | Mechanisms affecting HIF-1a stability by
directly modulating its ubiquitination status
A deubiquitinating enzyme potentially acts as a stabilizer of HIF-1a
because ubiquitinated HIF-1a may be rescued from degradation by
deubiquitination.
The first factor identified as a deubiquitinating enzyme for HIF-
1a was VDU2, also known as USP2066 (Table 2). The interaction
between HIF-1a and VDU2 was shown using an immunoprecipita-
tion assay. Molecular and cellular experiments showed that VDU2
interacted with HIF-1a in order to induce the expression of HIF-1
downstream genes, such as VEGF, through the deubiquitination and
stabilization of HIF-1a. Previous findings showing that VDU2 had no
clear effect on another ubiquitinated short-lived protein, p53, indi-
cated the target specificity of VDU2. Other deubiquitinating
enzymes (e.g. USP8) were also shown to stabilize HIF-1a67 (Table 2).
Furthermore, we also identified another deubiquitinating protein,
UCHL1,8 as described below (Table 2).
3.4 | Mechanisms regulating nuclear translocation
of HIF-1a
Translocation from the cytosol into the nucleus is another important
regulatory step in HIF-1 activity. HIF-1a has the ability to shuttle
between the nucleus and the cytoplasm.68 Carbonaro et al69 reported
that the HIF-1a protein associates with polymerized microtubules and
traffics to the nucleus when its NLS is recognized by the motor pro-
tein, dynein (Table 3). In addition to this mechanism, the AMPK-
HDAC pathway deacetylates the cytosolic molecular chaperone,
HSP70, promotes the interaction between HIF-1a and HSP90, and
facilitates the rapid nuclear accumulation of HIF-1a70 (Table 3).
In contrast, the active export of HIF-1a from the nucleus was
found to be important in the regulation of HIF-1 activity. Phosphory-
lation of the serine residues, Ser641 and Ser643, which are in close
proximity to an atypical nuclear export signal of HIF-1a (between
residues 632 and 639), by MAPK has been reported to block export
by chromosome region maintenance 1 protein homologue (CRM1),
thereby promoting nuclear accumulation and transcriptional activ-
ity68,71,72 (Figure 3B; Table 3).
3.5 | Mechanisms modulating HIF-1a and HIF-1b
heterodimer formation
After being stabilized, HIF-1a forms a heterodimer with the constitu-
tively expressed binding partner, HIF-1b. Heterodimer formation is
also an important regulatory step in the activation of HIF-1, and
CK1d was found to be involved in this process as a result of this
kinase activity on HIF-1a S24773 (Figure 3B; Table 3). A luciferase
assay to evaluate HIF-1 transcription activity showed that the
siRNA-mediated silencing of CK1d enhanced, whereas the overex-
pression of CK1d inhibited HIF-1 activity under hypoxic conditions.
The phosphorylation-defective mutation, S247A, enhanced, whereas
the corresponding phosphorylation-mimic mutation, S247Q, inhibited
heterodimerization, further suggesting the importance of the CK1d-
dependent phosphorylation of HIF-1a.
3.6 | Mechanisms regulating the transactivation
activity of HIF-1a
Regulation of the transactivation activity of HIF-1 is primarily modu-
lated by the hydroxylation of N803 by an oxygen-dependent
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dioxygenase other than PHD, namely, FIH-1 (Figure 2). Asparagine
hydroxylation prevents the acetyltransferases, p300/CBP, from inter-
acting with the C-terminal transactivation domain (C-TAD) of HIF-1a
and subsequently inhibits the recruitment of RNA polymerase II to
the promoter regions of the downstream genes of HIF-1. Thus, fac-
tors modulating this process including not only the asparagine
hydroxylation status, but also the efficiency of p300/CBP recruit-
ment have been found to affect the transactivation activity of HIF-1.
Another isoform of SIRT2, SIRT1, was shown to suppress the
transactivation activity of HIF-1a74 (Figure 3B; Table 3). HIF-1a is
acetylated by PCAF at K647 (Figure 3B; Table 3). SIRT1 deacetylates
it and represses HIF-1a activity by inhibiting the recruitment of
p300/CBP. SIRT1 was down-regulated under hypoxic conditions as a
result of reduced NAD(+) levels, which facilitated the acetylation and
activation of HIF-1a.
Yasinska and Sumbayev reported the importance of another
post-translational modification of HIF-1a, C800 S-nitrosylation, for
increases in the transactivation activity of HIF-1a75 (Figure 3B). S-
nitrosylation was previously reported to stimulate the recruitment of
p300 to the HIF-1a C-terminal domain in a GST pull-down assay.
The increase in HIF-1 activity was not observed when the cysteine
residue was substituted with alanine.
Chen et al recently reported that XBP1 is activated in triple-
negative breast cancers (TNBC) and plays a pivotal role in their
tumorigenicity and progression.76 From a mechanistic viewpoint,
they showed that XBP1 formed a transcriptional complex with HIF-





on HIF-1 activity Regulatory mechanisms for HIF-1 activity Reference
Stability of the HIF-1a protein by modulating its prolyl hydroxylation status
PHD1, 2, 3 Negative Hydroxylating P402 and P564 of HIF-1a for ubiquitination 17, 19, 20
Loss-of-function
mutant of SDH









mutants of IDH1, 2
Controversial L-2HG inhibits PHD activities leading to an increase in HIF-1a levels, whereas D-2HG
promotes PHD
51
L-2HG inhibits PHD activities leading to an increase in HIF-1a levels, whereas D-2HG has
no effect
52
IDH3 Positive Inactivating PHD through a decrease in 2OG level, when overexpressed aberrantly. 7
NQO1 Positive Binding to HIF-1a and physically preventing its interaction with PHD 53
SIRT2 Negative Deacetylating HIF-1a at K709 and enhancing the interaction between HIF-1a and PHD2 56
Stability of the HIF-1a protein without modulating its prolyl hydroxylation status
HSP90 Positive Protecting HIF-1a from RACK1-mediated and PHD-VHL-independent proteolysis 57
GSK-3 Negative Phosphorylating S551, T555, and S589 of HIF-1a for PHD-VHL-independent proteolysis 58
PLK3 Negative Phosphorylating S576 and S657 of HIF-1a for PHD-independent proteolysis 59
RSUME Positive SUMOylating HIF-1a for its stabilization 62
SENP1 Positive deSUMOylating HIF-1a to inhibit VHL-mediated ubiquitination in a PHD-independent
way
63
SET7/9 Negative Methylating HIF-1a at K32 for its ubiquitin-mediated proteolysis in a PHD-VHL-
independent way
64
LSD1 Positive Demethylating HIF-1a at K32 to suppress PHD-VHL-independent proteolysis 65
Stability of the HIF-1a protein by modulating its ubiquitination status




Positive Deubiquitinating HIF-1a for its stabilization 66
USP8 Positive Deubiquitinating HIF-1a for its stabilization 67
UCHL1 Positive Deubiquitinating HIF-1a for its stabilization 8, 77
D-2HG, D-2-hydroxyglutarate; FH, fumarate hydratase, FIH-1, factor-inhibiting HIF-1; GSK-3, glycogen synthase kinase 3; HSP, heat-shock protein;
IDH, isocitrate dehydrogenase; LSD1, lysine-specific demethylase-1; L-2HG, L-2-hydroxyglutarate; NQO1, NAD(P)H:quinone oxidoreductase 1; PHD,
prolyl-4-hydroxylase; PLK3, polo-like kinase 3; RACK1, receptor for activated C kinase; RSUME, RWD-containing SUMOylation enhancer; SDH, succi-
nate dehydrogenase; SENP, sentrin/SUMO-specific protease; SIRT, sirtuin; VDU, pVHL-interacting deubiquitinating enzyme; VHL, von Hippel-Lindau;
2OG, 2-oxoglutarate.
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1a, enhancing the expression of HIF-1a target transcripts by recruit-
ment of RNA polymerase II (Table 3). Depletion of XBP1 inhibited
tumor growth and relapse.
4 | SCREENING OF NOVEL UPSTREAM
ACTIVATORS OF HIF-1
We recently established a genetic screening method to investigate
novel genes responsible for the activation of HIF-1, and successfully
identified the following three genes as novel activators of HIF-1:
IDH3 (Tables 2 and 3), UCHL1 (Table 2), and LY6E6-8 (Table 1). We
reported that the forced expression of each promoted the malignant
progression and/or growth of tumors through a different mechanism
for the activation of HIF-1.
4.1 | IDH3-HIF-1 axis
Aberrant overexpression of wild-type IDH3a, a subunit of the IDH3
heterotetramer, significantly decreased 2OG levels and increased the
stability and transactivation activity of HIF-1a in cancer cells by inac-
tivating 2OG- as well as the oxygen-dependent dioxygenases
(Tables 2 and 3), PHD and FIH-1.7 However, the silencing of IDH3a
inhibited the Warburg effect and angiogenesis, resulting in a signifi-
cant delay in tumor growth. Clinically, a database-based Kaplan-
Meier analysis showed that the expression of IDH3a was associated
with the poor postoperative overall survival of lung and breast can-
cer patients. These findings support the use of IDH3 as a novel diag-
nostic and treatment target.
4.2 | UCHL1-HIF-1 axis
Regarding UCHL1, we showed that it stabilizes the HIF-1a protein
by deconjugating the VHL-mediated ubiquitin from HIF-1a8
(Table 2). In murine models of pulmonary metastasis, the aberrant
overexpression of UCHL1 was shown to promote distant tumor
metastases in a HIF-1-dependent way. In contrast, the inhibition of
the UCHL1-HIF-1 axis resulted in significant suppression of meta-
static tumor formation. Intratumoral expression levels of UCHL1
were found to correlate with those of HIF-1a and be strongly asso-
ciated with the poor overall survival of patients with breast and lung
cancers. These findings collectively provide a rationale for using
UCHL1 as a prognostic marker and therapeutic target of cancers. In
addition, we recently reported that UCHL1 increased the radioresis-
tance of cancer cells by producing the antioxidant, reduced glu-
tathione (GSH), through HIF-1-mediated reprogramming of the
glucose metabolic pathway.77
4.3 | LY6E-HIF-1 axis
Regarding LY6E, we showed that it induced HIF-1a expression princi-
pally at the transcription level6 (Table 1). This, in turn, increased the
expression levels of proangiogenic factors, such as VEGFA and plate-
let-derived growth factor subunit B (PDGFB), by decreasing those of
phosphatase and tensin homolog (PTEN) and subsequently activating
the PI3K/Akt pathway. The LY6E-mediated activation of HIF-1 was
found to eventually increase micro blood vessel density and promote
the growth of tumor xenografts in in vivo mouse models. Expression
levels of LY6E were significantly higher in human breast cancers than




impact on HIF-1 activity Regulatory mechanisms for HIF-1 activity Reference
Nuclear translocation
Dynein Positive Interacting with NLS of HIF-1a for the nuclear translocation of HIF-1a 69
AMPK/HDAC pathway Positive Triggering HIF-1a nuclear localization by deacetylating HSP70 and promoting
the HIF-1a-HSP90 interaction
70
MAPK Negative Phosphorylating S641 and S643 for the export of HIF-1a from the nucleus 71, 72
Heterodimer formation
CK1d Negative Phosphorylating HIF-1a at S247 to inhibit heterodimer formation with HIF-1b 73
Transactivation activity of the HIF-1a protein
FIH-1 Negative Hydroxylating N803 of HIF-1a to inhibit the interaction between HIF-1a and
p300/CBP
30, 31
SIRT1 Negative Inhibiting the HIF-1a-p300/CBP interaction by deacetylating HIF-1a K647,
which is acetylated by PCAF
74
XBP1 Positive Forming a transcriptional complex with HIF-1a and promoting the recruitment
of RNA polymerase II
76
IDH3 Positive Inactivating FIH-1 through a decrease in 2OG levels when overexpressed
aberrantly
7
AMPK, AMP-activated protein kinase; CBP, CREB-binding protein; CK1d, casein kinase 1d; FIH-1, factor-inhibiting HIF-1; HDAC, histone deacetylase;
HSP, heat-shock protein; IDH, isocitrate dehydrogenase; NLS, nuclear localization signal; PCAF, p300/CBP-associated factor; SIRT, sirtuin; 2OG, 2-oxo-
glutarate.
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in normal breast tissues, and were strongly associated with the poor
prognoses of patients with various cancers.
5 | CONCLUSION AND PERSPECTIVE
Hypoxia-inducible factor 1 has been associated with the malignant
progression and growth of cancers. Thus, HIF-1 has attracted consid-
erable attention as a target for cancer therapies and diagnoses, and
extensive efforts have been made to elucidate the mechanisms
responsible for its activation. Accumulating information suggested
that multiple mechanisms, in addition to the well-established mecha-
nisms, which are mediated by PHD-dependent hydroxylation, VHL-
dependent ubiquitination, and FIH-1-dependent hydroxylation, con-
tribute to the regulation of HIF-1 activity. Although molecular and
cellular research has shown individual mechanisms of action, the
mechanistic relationships among some of them remain largely
unknown. A clearer understanding of these mechanistic relationships
is critical for fully elucidating when, where, and how HIF-1 becomes
active and the application of this information to the development of
novel therapeutic strategies for cancers.
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